Cost of medication therapy in ambulatory HIV-infected patients

Annals of Pharmacotherapy

Volumn 31, Issue 3, 1997, Pages 303-307

  Nykamp, Diane ^a   Barnett, Candace W ^b   Lago, Maria ^c   Parham, Deborah L ^c   Fernandez, Enrique S ^d  

^a MERCER UNIVERSITY   (United States)

^b Mercer University School of Pharmacy   (United States)

^c US Bureau of Primary Health Care   (United States)

^d Bureau of Health Professions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ATOVAQUONE; CLINDAMYCIN; CLOTRIMAZOLE; DAPSONE; DIDANOSINE; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; PENTAMIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; AIDS RELATED COMPLEX; ARTICLE; CANDIDIASIS; CHILD; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; PUERTO RICO; UNITED STATES;

EID: 0031058849     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100306     Document Type: Article

References (14)

1. Branson BM. Early intervention for persons infected with human immunodeficiency virus. Clin Infect Dis 1995;20(suppl 1):S3-22.
2. Hellinger FJ. Forecasts of the cost of medical care for persons with HIV: 1992-1995. Inquiry 1992;29(Fall):356-65.
3. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA 1993;270:474-8.
4. Bjornson DC, Oster CN, Hiner WO Jr, Tramont EC, the Military Medical Consortium for Applied Retroviral Research. The relationship between outpatient drug costs and disease progression in the human immunodeficiency virus-infected population. DICP Ann Pharmacother 1991;25:414-7.
5. Kotzan JA, McMillian CA. The ratio of AIDS to non-AIDS Medicaid medical costs from 1992 to 2000. Clin Ther 1995;17:1320-9.
6. Bozzette SA, Parker R, Hay J. A cost analysis of approved antiretroviral strategies in persons with advanced human immunodeficiency virus disease and zidovudine intolerance. J Acquir Immune Defic Syndr 1994;7:355-62.
7. Centers for Disease Control and Prevention. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR Morb Mortal Wkly Rep 1995;44(RR-8):1-34.
8. Gross PA, Kaplan JE, Thair JP, Masur H, Wilfert CM, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. Clin Infect Dis 1995;21(suppl 1):S1-11.
9. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(RR-17):1-19.
10. 1995 Drug topics red book. Montvale, NJ: Medical Economics, 1995.
11. Weiss PJ, Kennedy CA, Wallace MR, Nguygen MT, Oldfield EC 3rd. Medication costs associated with the care of HIV-infected patients, Clin Ther 1993;15:912-6.
12. CPI detailed report/US Department of Labor, Bureau of Labor Statistics. Washington, DC: US Department of Labor, Bureau of Labor Statistics [Office of Prices and Living Conditions], 1995.
13. Greenblatt RM, Hollander H, McMaster JR, Henke CJ. Polypharmacy among patients attending an AIDS clinic: utilization of prescribed unorthodox, and investigational treatments. J Acquir Immune Defic Syndr 1991;4:136-43.
14. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, zalcitabine. N Engl J Med 1996;334:1011-7.